In November 2023, we opened a new clinical unit in Ostrava (CZ). We have now received all necessary certificates for operation (including European GCP), and client audits are currently underway.

In addition, preparations for the first studies are progressing well, and we estimate that very first study will be initiated by the second quarter of this year.

To remind you of the festive atmosphere of the ribbon-cutting ceremony, we have prepared a video of the opening speech below.

The speech was held by Stephan Holl, CEO of Conscio Group, Roman Grunt, CEO of Quinta – Analytica, Jiří Juchelka, PI of Quinta – Analytica, and in the name of cooperation by Cyril Kučera, Deputy for Medical Care of the Ostrava City Hospital.

Additional News

  • 16 December 2024

    Welcome, 2025!

    Reflecting on 2024 with gratitude and looking ahead with optimism.

  • 2 December 2024

    A Decade of Partnership with Adamed Pharma

    Adamed Pharma and Quinta-Analytica’s 10 – Year Journey in Pharma Innovation

  • 25 November 2024

    Expediting Biosimilar development: Streamlining the path from research to market

    On behalf of the Conscio Group, we would like to invite you to a free webinar on the future of the biosimilar pathway to approval, which is now open for registration.